Vaccines for Emerging Infectious Diseases Report 2018: Funding, R&D, and Global Partnership Strategies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Vaccines
for Emerging Infectious Diseases: Funding, R&D, and Global Partnership
Strategies”
report has been added to ResearchAndMarkets.com’s
offering.

“Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global
Partnership Strategies” finds that philanthropic organizations and
public-private partnerships like the Coalition for Epidemic Preparedness
Innovations (CEPI) are filling a niche for funding translational and
clinical vaccine research, allowing development of vaccines for diseases
such as Lassa fever to occur even in the absence of an ongoing epidemic.
As of November 2018, there were 235 vaccines in preclinical
investigation, clinical development, or marketed for twelve major EIDs*.

Major EIDs include Zika, Ebola, MERS, Lassa, Marburg, Severe Acute
Respiratory Syndrome (SARS), Chikungunya, CCHF, West Nile, Dengue,
Yellow Fever, H5N1.

This report covers current and future challenges for the development and
deployment of vaccines for EIDs, focusing on vaccine platform technology
and research, funding mechanisms, and collaborative global partnerships.

Key Topics Covered:

1. Preface

2. Executive Summary

  • Key Findings
  • KOL Insights on Vaccines for Emerging Infectious Diseases

3. Overview of Emerging Infectious Diseases

  • Defining Emerging Infectious Diseases (EIDs)
  • Drivers of Emerging Infections & Routes of Transmission
  • Key EIDs
  • Ebola Virus Disease
  • Zika Virus Disease
  • Middle East Respiratory Syndrome (MERS) and Other EIDs

4. Clinical Trial Design

  • Clinical Trial Design Challenges
  • Randomization Units
  • Selection of Clinical Trial Population and Comparator
  • Additional Strategies for Vaccine Approvals
  • Unmet Needs in Clinical Trial Design

5. Vaccine Platform Technologies

  • Overview of Vaccine Platform Technologies
  • Vaccine Platforms By Stage of Development
  • Live-attenuated Vaccines
  • Viral Vector-Based Vaccines
  • DNA Vaccines
  • Whole-Inactivated Vaccines, Subunit Vaccines, and VLPs

6. Funding and Market Incentives

  • Funding Sources for Vaccines for EIDs
  • Push and Pull Incentives
  • Challenges for Funding of Vaccine Development
  • Lessons from the Ebola and Zika Outbreaks

7. Global Collaborations for Vaccine Development

  • Global Vaccine Development Fund and Priority Diseases
  • Coalition for Epidemic Preparedness Innovations (CEPI)
  • Vaccine Preparedness
  • Global Virome Project (GVP) and Other Public-Private Partnerships

8. Pipeline Vaccines for Key Emerging Infectious Diseases

  • Clinical Development of Vaccines for EIDs
  • Ebola Vaccine Pipeline
  • Zika Vaccine Pipeline
  • MERS-CoV Vaccine Pipeline

9. Surveillance and Healthcare Infrastructures

  • Disease Surveillance for EIDs
  • Logistical Challenges for Vaccine Delivery
  • Vaccine Preparedness
  • Unmet Needs in Basic Vaccine Research

Companies Mentioned

  • Bharat Biotech
  • Emergent Biosolution
  • IDT Biologika
  • Imutex
  • Inovio
  • Integrated Biotherapeutics
  • Johnson & Johnson/Janssen
  • GeneOne Life Science
  • GlaxoSmithKline
  • NewLink Genetics
  • Merck
  • Novartis
  • Novavax
  • Pfizer
  • Profectus

For more information about this report visit https://www.researchandmarkets.com/research/zhwzpx/vaccines_for?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Disease Testing
, Vaccines